Pressmeddelande

BioStock: Alligator’s CEO on current development and the rights issue

Cision Publicerad: 21 Mar 09:13

The recent phase II success with mitazalimab means that Alligator Bioscience can now start preparing for phase III. Besides mitazalimab, the Lund-based biotech also has other promising projects in its pipeline. Now, Alligator is carrying out a SEK 150.9 million rights issue to bring all of the projects even further. BioStock talked to CEO Søren Bregenholt to discuss the rights issue in more depth.

Read the article at biostock.se:

Alligator’s CEO on current development and the rights issue - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Alligator Bioscience

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!